{"protocolSection":{"identificationModule":{"nctId":"NCT01915459","orgStudyIdInfo":{"id":"HG-13-01"},"organization":{"fullName":"Hugel","class":"INDUSTRY"},"briefTitle":"Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity","officialTitle":"A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity"},"statusModule":{"statusVerifiedDate":"2015-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-06"},"primaryCompletionDateStruct":{"date":"2014-05","type":"ACTUAL"},"completionDateStruct":{"date":"2014-07","type":"ACTUAL"},"studyFirstSubmitDate":"2013-08-01","studyFirstSubmitQcDate":"2013-08-02","studyFirstPostDateStruct":{"date":"2013-08-05","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-04-30","lastUpdatePostDateStruct":{"date":"2015-05-04","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hugel","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to Botox® reducing upper limb muscle tone in post stroke patients."},"conditionsModule":{"conditions":["Stroke","Spasticity"],"keywords":["Stroke","Spasticity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":186,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Botulinum toxin type A(Botulax®)","type":"EXPERIMENTAL","description":"Botulinum toxin type A","interventionNames":["Biological: Botulinum toxin type A(Botulax®)"]},{"label":"Botulinum toxin type A(Botox®)","type":"ACTIVE_COMPARATOR","description":"Botulinum toxin type A","interventionNames":["Biological: Botulinum toxin type A(Botox®)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A(Botulax®)","description":"IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone","armGroupLabels":["Botulinum toxin type A(Botulax®)"]},{"type":"BIOLOGICAL","name":"Botulinum toxin type A(Botox®)","armGroupLabels":["Botulinum toxin type A(Botox®)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The change in MAS(Modified Ashworth Scale) grade","description":"The change in MAS (Modified Ashworth Scale) grade from baseline at week 4 for wrist flexor muscle tone","timeFrame":"from baseline at week 4"}],"secondaryOutcomes":[{"measure":"The change in muscle tone on MAS (Modified Ashworth Scale)for elbow, finger, and thumb flexor","timeFrame":"from baseline at week 4"},{"measure":"The change in muscle tone on MAS (Modified Ashworth Scale)for wrist, elbow, finger, and thumb flexor","timeFrame":"from baseline at week 8 and 12"},{"measure":"The change in DAS (Disability Assessment Scale) grade for the principal therapeutic target","timeFrame":"from baseline at week 4, 8, 12"},{"measure":"Global assessment evaluated by investigator","timeFrame":"at week 4, 8, 12"},{"measure":"Global assessment evaluated by patients","timeFrame":"at week 4, 8, 12"},{"measure":"The change in carer burden on Caregiver Burden Scale evaluated by caregiver","timeFrame":"from baseline at week 4, 8, 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male and Female patients, over 20 years of age\n2. Patients with a history of stroke more than 6weeks prior to enrollment\n3. Focal spasticity of wrist flexor measured with Modified Ashworth Scale (MAS) of 2 or greater at wrist and 1 or greater at least one of elbow flexor and finger flexor\n4. A minimum grade of 2 or greater on the Disability Assessment Scale(DAS) for targeted one functional disability item (i.e., hygiene, dressing, pain, or limb position)\n5. Patients who signed informed consent form, clearly understand the intent of the study and are able to comply with instructions to complete the entire study\n\nExclusion Criteria:\n\n1. Patients with diagnosed neuromuscular disorders such as Lamber-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis\n2. Patients with profound atrophy of the muscle in the target limb\n3. Patients with fixed joint/muscle contracture\\* in the target limb\n\n   * Defined as inability to passively move the joints\n4. Patients with history within 6 months or planned to have treatment with phenol or alcohol injection(chemodenervation) in the target limb\n5. Patients with history within 6 months or planned to have treatment with tendon lengthening in the target limb\n6. Patients who have concurrent treatment with an intrathecal baclofen\n7. Patients who had received Botulinum toxin injection within the past 3 months(for cosmetic purpose is allowed)\n8. Patients with concurrent or planned to take muscle relaxants and/or benzodiazepine medication (Allowed to participate if patient has consistently taken these medication from a month before screening visit and no changes in therapy are planned during the study)\n9. Patients with concurrent or planned to have physical, occupational, or splinting therapy (Allowed to participate if these therapies were consistently taken from a month before screening visit and no treatment changes are planned during the study\n10. Patients with a known allergy or sensitivity to the study medication or its components (Clostridium botulinum toxin type A, albumin, Sodium chloride, etc.)\n11. Patients who have participated in other clinical trials 1 month prior to this study\n12. Male and Female who are not willing to take any appropriate means of contraception or to have ascetic life at least 2 months after treatment\n13. Patients who are not eligible for this study at the discretion of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Min-ho Chun, Ph.D.","affiliation":"Asan Medical Center","role":"STUDY_CHAIR"}],"locations":[{"facility":"Seoul National University Hospital","city":"Bundang","state":"Kyunggi","country":"Korea, Republic of"},{"facility":"The Catholic University of Korea Incheon St. Mary's hospital","city":"Incheon","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Asan Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Chung Ang University Hospital","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Gangnam Severance Hospital","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"SMG-SNU Boramae Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}